Indian Patents. 279304:AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM

Title of Invention	AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM
Abstract	The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyI-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-355-dihydroxyhept-6-enoic acid calcium of Formula I,

Full Text	FIELD OF THE INVENTION The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6" enoic acid calcium of Formula I, The present invention is an improvement in or modification of the invention disclosed and claimed in our co-pending application no 277/CHE/2007, BACKGROUND OF THE INVENTION Rosuvastatin, which is an antihyperchlolesterolemic drug, is chemically known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium (2:1) salt of Formula I. Rosuvastatin was for the first time disclosed in US 5,260,440. Rosuvastatin is being marketed under the proprietary name CRESTOR, as an oral tablet, for the treatment of hypercholesterolemia. In view of the importance of rosuvastatin as a lipid-lowering agent, several synthetic methods have been reported in the literature to prepare rosuvastatin, some of which are summarized below: US 5,260,440 disclose a process for preparing rosuvastatin in examples. The process is as shown below: The difficulties in the above process are that the intermediate (A) is not obtained in pure form readily. Further, its purification is tedious and overall yield is extremely low. Even when intermediate (A) is obtained in pure form, further condensation with intermediate (11) to form rosuvastatin, does not result in rosuvastatin of right quality as the product contains unacceptable quantity of impurity levels. WO 03/097614 A2 describes a modified procedure for the preparation of the starting material 4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-carboxaldehyde and its further conversion to rosuvastatin by condensing with methyl (3R)-3-[(tert-butyldimethylsilyl)oxy]-5-oxo-6-triphenylphosphoranylidene hexanoate. The condensed product was deprotected using methanesulfonic acid and subsequently converted to rosuvastatin calcium (2:1) salt. WO 2004/052867 Al describes a process to prepare rosuvastatin by condensing 1-cyano (2S)- 2-[(tert-butyldimethylsilyl)oxy]-4-oxo-5-triphenylphosphoranylidenepentane with 4-(4- fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino]pyrimidin-5-carbaldehyde and subsequent deprotection of silyl group, followed by reduction and hydrolysis. WO 2000/049014 Al discloses a novel chemical process for the manufacture of tert-butyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}-(4R,6S)-2,2-dimethyl[l,3]dioxan-4-yl)acetate, which comprises reaction of diphenyl {4-(4-fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino]pyrimidin-5-yl-methyl}phosphineoxide with tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-l,3-dioxan-4-yljacetate and its further conversion to rosuvastatin. WO 2004/014872 Al describes a process for the manufacture of rosuvastatin calcium (2:1) salt, which comprises mixing a solution of calcium chloride with a solution of water soluble salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid. This process for the preparation of rosuvastatin employs the use of phosphorane side chain, the preparation of side chain requires eight synthetic steps and involves expensive reagents. The process is both uneconomical and time consuming, hence not appropriate for commercial scale operation. WO 2006/100689 Al discloses a process for preparation of rosuvastatin as shown below: In the above scheme R1, R2, R3 represent substituted or unsubstituted phenyl and R4 represents an aliphatic residue selected from C1-C4 alkyl, R5 represents C1-C4 alkyl which is optionally substituted by hydroxyl, R6 represents hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy, R7 represents aliphatic residue, R8 represents C1-C4 alkyl. WO 2006/106526 Al describes the preparation of rosuvastatin as shown below: In the above mentioned scheme R1, R2, R3 are substituted or unsubstituted phenyl and R4 is an aliphatic residue selected from C1-C4 alkyl, R5 represents C1-C4 alkyl, M is an alkali metal salt, X represents a halogen, R6 represents C1-C4 alkyl which is optionally substituted by hydroxyl, R7 represents hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy, R8 is an aliphatic residue selected from C1-C4 alkyl. As mentioned above though there are a number of processes available still there is a continuing need to identify alternative processes for the manufacture of rosuvastatin and its pharmaceutically acceptable salts. Such processes may, for example, when compared to previously known processes, be more convenient to use, be more suitable for large scale manufacture, give the product in a better yield, reduce the number of steps involved, use intermediates which are more easily isolated, require less complex purification techniques, use less expensive reagents and/or be more environmentally friendly. We have now found an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl- 2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept"6-enoic acid calcium of Formula I OBJECTIVE The objective of the present invention is to provide an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium with high yield and high purity. In yet another objective of the present invention is to provide an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium, which is simple, industrially applicable and economically viable. SUMMARY OF THE INVENTION The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5"yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula I, wherein R3 represents CM straight chain or branched chain alkyl, aryl, substituted aryl, aralkyl; M represents Mg, Zn, Ca, Cu; n represents an integer selected from 1-3; Ri represents alkyl or alkoxy; m represents an integer selected from 0 or 1; in an organic solvent to obtain a compound of Formula VI, wherein R3 is as defined above, c) deprotecting the compound of Formula VI with a suitable reagent in an organic solvent, water or mixtures thereof to obtain compound of Formula VII, wherein R3 is as defined above, d) reducing the compound of Formula VII to obtain a compound of Formula VIII, DETAILED DESCRIPTION OF THE INVENTION The compound of Formula III is protected with a suitable hydroxy protecting group selected from tert-butyldimethylsilyl chloride, 2,3-dihydropyran, trimethylsilylchloride, methoxymethyl chloride, more preferably tert-butyldimethylsilyl chloride. The hydroxy protection is carried out in an organic solvent in presence of bases like imidazole, triethylamine. The usage of base is essential for completion of silylation. The organic solvent used for the above silylation reaction is selected from tetrahydrofuran, dimethoxy ethane, dioxane, dichloromethane, ethylene dichloride, N, N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidinone, sulfolane, more preferably N,N-dimethylformamide etc. Also during this silylation reaction a suitable additive is added to accelerate silylation, which is selected from sodium iodide, potassium iodide, lithium iodide etc. The reaction is conducted at a temperature in the range of 0°-128°C, more preferably 50-80°C. The compound of Formula IV is isolated as an oily mass, which is sufficiently pure for the next step. The hydroxy protected compound of Formula IV is treated with acid activator like 1,1- carbonyldiimidazole, or methyl chloroformate, ethyl chloroformate, phenyl chloroformate, 4- methoxyphenylchloroformate, 4-chlorophenylchloroformate, 2,4-dinitrophenylchloroformate, 4-trifluoromethylphenylchloroformate, 4-nitrophenylchloroformate, 2- nitrophenylchloroformate, etc, more preferably 1,1-carbonyldiimidazole. This reaction is carried out in presence or absence of organic base. The organic base is selected from triethylamine, pyridine etc. The resulting activated imidazolimide intermediate is subsequently treated with magnesium complex of monoalkyl malonate or zinc complex of monoalkyl malonate. Magnesium complex of monoalkyl malonate can be prepared by treating 2 moles of malonic acid mono alky! ester with 1 mole of magnesium ethoxide. This homologation is conducted at a temperature between 0-100°C, preferably at ambient temperature. The organic solvent used in the homologation is selected from tetrahydrofuran, MiV-dimethylformamide, methylene dichloride, acetonitrile or mixtures thereof Zinc complex of monoalkyl malonate can be prepared using different methods. Process 1: Zinc complex is prepared by reacting dialkyl zinc with 2 moles of lower alcohol, preferably ethanol in an inert solvent such as tetrahydrofuran, toluene, hexane, methyl tert-butyl ether, isopropyl ether or mixtures thereof, at -10°C to 40°C, preferably 5 to 25^C. 1 to 5 moles of monoalkyl malonate, preferably 2 to 3 moles are added to this reaction mixture and stirred for 5 h 15 h, preferably 6 -12 h. Process 2: Zinc complex is prepared by reacting dialkyl zinc with 1 to 5 moles of monoalkyl malonate, preferably 2 to 3 moles in an inert solvent such as tetrahydrofuran, toluene, hexane, methyl tert-butyl ether, isopropyl ether or mixtures thereof., at ambient temperature for 5 h to 15 h, preferably 6 h to 12 h. Process 3: Zinc complex is prepared by reacting zinc oxide with 1 to 5 moles of monoalkyl malonate in an inert solvent such as tetrahydrofuran, toluene, hexane, methyl tert-butyl ether, isopropyl ether or mixtures thereof, at ambient temperature for 5 h to 10 h. The water formed during the course of reaction is co-distilled with an inert solvent such as toluene. The metal complex of Formula V, is treated with acid activated compound of Formula IV, in an inert solvent such as tetrahydroftiran, acetonitrile, toluene, methyl tert-butyl ether, isopropyl The deprotection of the compound of Formula VI to yield product of Formula VII, is carried out using acids having a general Formula HX wherein X represents halide or MX wherein X represents halogen, M is cation derived from like inorganic metal like Na"^, K^, Li^ etc or organic amine like N'4(R)4 where in R represents C1-C4 alkyl, straight or branched chain alkyl sulfonic acids such as para toluene sulfonic acids, methanesulfonic acids, trifluormethane sulfonic acid, organic acids such as formic acid, trifluroacetic acid, acetic acid in aqueous solvent or in a mixture of organic solvent at room temperature. The reaction is preferably conducted in organic solvent, water or mixtures thereof The organic solvent can be selected from tetrahydrofuran, acetonitrile, methanol, ethanol, dichloromethane, ethylene dichloride, toluene, xylene etc. The compound of Formula VII is stereoselectively reduced with metal borohydride in presence of chelating agent like trialkylborane or boronates selected from dialkyl alkoxy boran such as diethyl methoxy borane, diethyl ethoxy borane, dimethyl ethoxy borane, dimethyl methoxy borane, more preferably diethyl methoxy borane. The stereoselective reduction is carried out in a mixture of inert solvent preferably tetrahydrofuran and lower alkanol, more preferably methanol at -78°C to -0°C. The metal borohydride employed is selected from sodium borohydride, potassium borohydride, calcium borohydride, more preferably sodium borohydride. After completion of reaction, excess borohydride is destroyed by acetic acid and resulting compound of Formula VIII is extracted into an organic solvent. The organic layer is concentrated under reduced pressure to give crude compound of Formula VIII, which is purified or used as such for hydrolysis. Saponification of compound of Formula VIII is carried out using a base, such as alkali metal hydroxide selected from sodium hydroxide, potassium hydroxide, calcium hydroxide. Preferably sodium hydroxide is used. The sodium salt of rosuvastatin thus obtained can be optionally isolated or the solution containing of rosuvastatin sodium is treated with benzathine acetate to get the corresponding benzathine salt, which can be further converted to rosuvastatin calcium. Alternatively, aqueous sodium salt of rosuvastatin can be treated with calcium ion source to give rosuvastatin calcium. The preparation of compound of Formula III is elaborated in our co-pending application number 1994/CHE/2006 filed in Chennai, India. The invention is illustrated with the following examples, which are provided by way of illustration only and should not be construed to limit the scope of the invention. EXAMPLE 1 PREPARATION OF ETHYL.6-(E).7.[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2.[iV- METHYL-iV-METHYLSULFONYLAMINO]PYRIMIDIN-5.YL]-(5S)-5-(t- BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE 20% w/v Diethyl zinc in toluene (10 ml) was added to toluene (50 ml) and cooled to 10-15°C. Ethanol (1,9 ml) was added at the same temperature to the reaction mixture and stirred for 12 h at 25-30°C. Thereafter, the resulting clear solution was treated with a solution of monoethyl malonate (3.91 g) in toluene (50 ml) and stirred for 6 h at room temperature. Ethanol, a byproduct from the reaction mass was removed by co-distillation with toluene at 40-45°C. The resulting mass was diluted with toluene and further treated with a solution of Imidizolyl-(4E)-5[4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-A^-methylsulfonylamino]pyrimidin-5-yl]-(3S)-3-(t-butyldimethylsilyloxy)pentenoate (6 g) in toluene (30 ml) at room temperature and the reaction mass was stirred for 40 h for completion of coupling reaction. After the reaction, mass was quenched with 5 % aqueous citric acid. The separated organic layer was washed with aqueous bicarbonate and finally with water. The crude product obtained after evaporation of solvent was purified by column chromatography. (Silica gel; Hexane : Ethylacetate mixture) Yield: 2 g 'HNMR (CDCb, 300 MHz): 003 (s, 6H), 0.85 (s, 9H), 1.24 (d, 6H), 1.26-1.29 (t, 3H), 2,49 (d,lH), 2.50 (d,lH), 2.65 (septet, IH), 3.4 (s,2H), 3.5 (s,3H), 3.5 (s, 3H), 3.56 (s, 3H), 4.1 (q, 2H), 4.56-4.58 (m, IH), 5.48 (dd, IH), 6.55 (d, IH), 7.1 (m, 2H), 7.58 (dd, 2H). EXAMPLE 2 PREPARATION OF ETHYL-6-(E).7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[A^- METHYL-7V-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL].(5S)-5-(t- BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE Zinc oxide (0.243 g) was suspended in toluene (50 ml) and monoethyl malonate (1.45 g) in toluene (10 ml) was added at 25-30°C and stirred for 3 h. To the resulfing clear solution imidazolyl-(4E)-5-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]-pyrimidin"5-yl]-(3S)-3-(t-butyldimethylsilyloxy) pentenoate (1.85 g) in tetrahydrofuran (5 ml) was added at 20-30°C and stirred the reaction mass at room temperature for 18 h. After the completion of coupling reaction, the reaction mass was quenched by the addition of aqueous citric acid and the organic layer was separated and washed with aqueous sodium bicarbonate followed by water. The organic layer was concentrated to yield crude compound. The crude compound obtained after evaporation of solvent was purified by column chromatography to yield the compound in pure form. Yield: 1.3 g EXAMPLE 3 PREPARATION OF ETHYL-6-(E)-7-[4-(4.FLUOROPHENYL)-6-ISOPROPYL-2-[N- METHYL-N.METHYLSULFONYLAMINO]PYRIMIDIN-5-YL].(5S)-5-(t- BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE 20% w/w Diethyl Zinc in toluene (10 ml) was diluted with toluene under N2 atmosphere at 0- 5°C and then treated with a solution of monoethyl malonate (3.91 g) in toluene (10 ml) at 20- 30°C. The resulting solution was stirred for 4 h at 25-30°C for complex formation and further treated with imidazolyl-(4E)-5[4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-A^- ethylsulfonylamino]-pyrimidin-5yl]-3-(S)-3-(t-butyldimethylsilyloxy)-pentenoate (5.5 g) in toluene (15 ml) and stirred at room temperature for 21 h for completion of coupling reaction, and product precipitates out. The crude compound obtained was purified by column chromatography. Yield: 2.3 g EXAMPLE 4 PREPARATION OF t.BUTYL-(6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[7V- METHYL-iV-METHYLSULFONYLAMIN01PYRIDIN-5-YL}-(5S)-5-(t- BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE. Diethyl zinc (10 ml, IM, solution in hexane) was added to tetrahydrofuran (20 ml) at 10-15^C and a mixture of ethanol (0.92 gm, 0.02 mol) and tetrahydrofuran (2ml) was added drop wise into the above diethyl zinc solution over a period of 10-15 min. The reaction mass was stirred at the same temperature for 30 min and mono-t-butyl malonate (3.2 gm, 0.02 mol) was added to the reaction mass drop wise after diluting with tetrahydrofuran (10 ml). The mixture was stirred for two hours and imidazolyl-5-{4-(4-fluorophenyl)-6-isopropyl-2-[A^-methy-A^-methylsulfonylamino]pyrimidin-5-yl}-(3S)-3-(t-butyldimethylsilyloxy] heptenoate (2.5gm), dissolved in tetrahydrofuran (10 ml) was added to it slowly over a period of 20 min. The reaction was stirred for 16 h at 20-25°C and quenched by adding water (20 ml) drop wise into the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with water (50 ml) and dried over sodium sulfate. The solvent was distilled out under reduced pressure (50-100 mm Hg) at 35-40°C to obtain the crude product as an oily mass, which was further purified by column chromatography using hexane, ethyl acetate. (9:1 v/v) as an eluant. Yield: 2.5 g ^HNMR (CDCl3,300 MHz): 0.1 (s, 6H), 0.93 (s,QH), 1.27 (d, 6H), 1.48 (s, 9H), 2.53 (dd, 2H), 3.33 (septet, IH), 2.36 (s, 2H), 3.53 (s, 3H), 3.58 (s, 3H), 4.53^7.55 (m, IH), 5.52 (dd, IH), 6.58 (d, IH), 7.01 (t, 2H), 7.62 (dd, 2H). EXAMPLE 5 PREPARATION OF t.BUTYL-(6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[N-METHYL-N-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL}.(5S)-5-HYDROXY-3-OXO HEPTENOATE t-Butyl(6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino] pyrimidin-5-yl}-(5S)-5-[t-butyl dimethylsilyloxy)-3-oxo heptenoate (2.5 gm) was dissolved in tetrahydrofuran (10 ml) at 25-30°C and tetrabutyl ammonium fluoride (5 ml, IM solution in tetrahydrofuran) was added to it drop wise over a period of 15 min. The mixture was stirred for 30 min at 25-30°C and quenched with aqueous sodium carbonate (25 ml, 10 % w/v). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with D.M water (25 ml) and solvent was evaporated under reduced pressure at 35-40°C to obtain the product as an oily mass. The product obtained was used as such for the subsequent reaction without further purification. Yield: 2 g 1H NMR (CDCU, 300MHz): L27 (d, 6H), 1.47 (S, 9H), 2.39 (d, 2H), 3.37 (septet, IH), 3.38 (brs, IH), 3.53 (s, 3H), 3.58 (s, 3H), 4.51-4.53 (m, IH), 5.5 (dd, IH), 6.65 (d, IH), 7.09 (f, 2H), 7.65 (dd, 2H). EXAMPLE 6 PREPARATION OF t-BUTYL-(6E)-7-{4-(4.FLUOROPHENYL)-6-ISOPROPYL-2-[A^-METHYL-7V-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL}-(3R,5S)-3,5-DIHYDROXY HEPTENOATE t-Butyl-(6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-iV-methylsulfonyl-amino]pyrimidin-5-yI}-(5S)-5-hydroxy-3-oxo heptenoate (2 g, 0.003 mol) was dissolved in tetrahydrofuran (54 ml) and methanol (14 ml) at 25-30°C under nitrogen atmosphere. The mixture was cooled to -78°C and diethylmethoxy borane (1 ml, 48 % solution in tetrahydrofuran, 0.004 mol) was added to it drop wise at -78°C over a period of 10 min. The mixture was stirred at -75°C to -78°C for one hour and sodium borohydride (0.14 gm, 0.003 mol) was added to it slowly over a period of 15 min. It was stirred for 2 h at -75°C to -78°C and quenched by adding acetic acid (2 ml) at -78°C. Saturated aqueous sodium bicarbonate solution (50 ml) was added to it and stirred for 15 min. The organic layer was separated and aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with water (25 ml) and dried over sodium sulfate. The solvent was distilled out at 35-40°C under reduced pressure to obtain the title compound. Yield: 2 g ^HNMR: 1.27 (d, 6H), 1.47 (s, 9H), 1.50-1.58 (m, IH), 2.38 (d, 2H), 3.37 (septet, IH), 3.51 (s, 3H), 3.57 (s, 3H), 3.63 (bs, IH), 3.80 (bs, IH), 4.15-4.18 (m, IH), 4.44-4.48 (m, IH), 5.46 (dd, IH), 6.64 (d, IH), 7.09 (t, 2H), 7.65 (dd, 2H). EXAMPLE 7 PREPARATION OF ETHYL-6-(E).7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[7V-METHYL-N-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL]-(5S)-HYDROXY-3-OXO HEPTENOATE Ethyl 6-(E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]-pyrimidin-5-yl]-(5S)-5-(t-butyldimethylsilyloxy)-3-oxo heptenoate (5 g) in acetonitrite (3 ml) was added to aqueous hydrofluoric acid (6.2 ml, 48 % w/w) at 0-5°C in 15 min. The temperature of the reaction mass was raised to 25-30°C and stirred for 2 h for completion of silyl cleavage. The reaction mixture was basified with aqueous sodium bicarbonate solution and the product was extracted with ethyl acetate (50 ml). The ethyl acetate layer was washed with water, dried over sodium sulphate and concentrated to give crude product (3 g). The crude product obtained was purified using column chromatography with ethyl acetate / hexane as eluant to yield pure title compound as an oil. WMR (CDCI3, 300 MHz): 1.25 (d, 6H), 1.27-1.29 (t, 3H), 2,65 (d, 2H), 3.34 (septet, IH), 3.44 (s, 2H), 3.52 (s, 3H), 3.57 (s, 3H), 4.22 (t, 2H), 4.51-4.55 (m, IH), 5.4 (dd, IH), 6.64 (d, IH), 7.08 (m, 2H), 7.63 (dd, 2H). EXAMPLE 8 PREPARATION OF (4E)-5-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL- (METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL}-(3S)-3-(0-TERT- BUTYLDIMETHYLSILYL)-4-PENTENOICACID tert-Butyldimethylsilyl chloride (7.6 g, 0.05 mol) was dissolved in A^,7V-dimethylformamide (25 ml) and anhydrous potassium iodide (8.4 g, 0.05 ml) was added to it at 25°C. The mixture was heated to 60°C and stirred for 30 min. Triethylamine (7 g, 0.06 mol) was added to the above hot reaction mixture and stirred for 10 min at 60°C. Subsequently (4E)-5-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyridin-5-yl-(3S)-3-hydroxy-4-pentenoic acid (10 g, 0.02 mol) was dissolved in iV^A^-dimethylformamide (25 ml) and added to the above reaction mixture drop wise over a period of 30 min at 60°C. The reaction mass was further stirred at 60°C for 2 h and cooled to room temperature. The reaction mass was quenched by adding DM water (50 ml) and product was extracted in toluene (2 x 50 ml). The toluene layer was washed with aqueous sodium bicarbonate (50 ml) followed by aqueous saturated sodium chloride (50 ml). The solvent was removed under reduced pressure to yield title compound as an oily mass, which was pure enough for the subsequent reaction. Yield: 12 g (95%) ^HNMR (CDCI3, 300 MHz): 0.05 (s, 6H), 0.89 (s, 9H), 1.27-1.30 (m, 6H), 2.38-2.50 (m, 2H), 3.40 (m, IH), 3.54 (s, 3H), 3.59 (s, 3H) 4.52 (brs, IH), 5.50-5.61 (m, IH), 6.58 (d, IH, J=15Hz), 7.0-7.18 (m, 2H), 7.60-7.66 (m, 2H). EXAMPLE 9 PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6.ISOPROPYL.2- [METHYL-(METHYLSULFONYL)AMINO]PYRIMIDIN-5.YL}.(5S)-5-(0- TERTBUTYLDIMETHYLSILYL)-3-OXO-HEPT-6-ENOATE (4E)-5-{4-(4-Fluorophenyl)-6"isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-(3S)-3-(0-tert-butyldimethylsilyl)-4-pentenoic acid (10 g, 0.018 mol) was dissolved in tetrahydrofliran (180 ml) and a solution of 1,1-carbonyldiimidazole (5.3 g, 0.03 mol) in tetrahydrofuran (30 ml) was added to the above reaction mass drop wise over a period of 30 min. The reaction mass was stirred overnight and magnesium salt of ethyl malonate (prepared in situ by stirring magnesium alkoxide (2.27 g) and monomethyl malonate (5.0 g) in tetrahydrofuran 30 ml at 25°C) was added drop wise into the reaction mass. The reaction mass was stirred for additional 20 h. After completion of the reaction, tetrahydrofuran was distilled out and redissolved the mass in a mixture of toluene (500 ml) and ethyl acetate (100 ml). The resulting organic layer was washed with aqueous sodium carbonate (500 ml) followed by DM water (2 x 500 ml). Thereafter, the organic layer was concentrated completely at 45-50°C under reduced pressure to obtain the crude title compound. The crude compound obtained was used for the subsequent reaction without ftirther purification. Yield: 8.75 g EXAMPLE 10 PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5^YL}-(5S)-5-HYDROXY-3-OXO HEPT-6-ENOATE Ethyl (6E)-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-(5S)-5-(0-tertbutyldimethylsilyl)-3-oxo-hept-6-enoate (10 g, 0.016 mol) was dissolved in acetonitrile (250 ml) at 25°C and the reaction mixture was cooled to 0°C. Hydrofluoric acid (48 %, 15 ml) was diluted in acetonitrile (250 ml) and added slowly to the above reaction mass over a period of 20 min at 0-5°C. After addition, the reaction mass was quenched by addition of 10 % aqueous sodium bicarbonate solution (50 ml). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (50 ml). The combined organic layer was washed with DM water (50 ml) and solvent distilled out under vacuum at 40-45°C to obtain the product as an oily mass. Yield: 8.25 g (66%) 'HNMR (CDCI3, 300 MHz): 1.25-1.32 (m, 9H), 2.67 (d, 2H, J=6Hz), 3.30-3.39 (m, IH), 3.46 (s, 2H), 3.53 (s, 3H), 3.59 (s, 3H), 4.12-4.20 (m, 2H), 4.56 (brs, IH), 5.40 (dd, J=15Hz, 6Hz), 6.68 (d, J=15Hz, IH), 7.09-7.28 (m, 2H), 7.62-7.67 (m, 2H). EXAMPLE 11 PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL-(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL}(3R,5S)-3,5- DIHYDROXY-HEPT-6-ENOATE Ethyl (6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl}(5S)-3-oxo-hept-6-enoate (10 g, 0.02 mol) was dissolved in a mixture of tetrahydrofuran (500 ml) and methanol (70 ml) at 25°C. The mixture was cooled to -78°C and diethylmethoxyborane (48 % in tetrahydrofuran, 5 ml, 0.02 mol) was added to the above cooled reaction mass at -75°C to -78°C over a period of 20 min. The reaction mass was stirred at -75°C to -78°C for 30 min before adding sodium borohydride (1 g, 0.02 m). The mixture was stirred for another 2 h at -78°C and quenched by adding acetic acid (13 g). Thereafter, saturated sodium bicarbonate solution (500 ml) was added to it and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with ethyl acetate (250 ml) and the combined organic layer was washed with DM water (250 ml). The organic layer obtained during the above process was concentrated at 40-45 °C under vacuum to get the crude product, which was used for hydrolysis as such without further purification. Yield: 10 g (99%) 'HNMR (CDCI3, 300 MHz): 1.22-1.30 (m, 9H), 1.46-1.53 (m, 2H), 2.46 (d, J=6Hz, 2H), 3.34-3.38 (m, IH), 3.52 (s, 3H), 3.58 (s, 3H), 4.15-4.28 (m, 2H), 4.95 (brs, IH), 5.45 (dd, J=15Hz, 6Hz). EXAMPLE 12 PREPARATION OF ETHYL (6E)-7-(4-(4.FLUOROPHENYL).6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINOPYRIMIDIN-5-YL] (3R,5S)-3,5- DIHYDROXYHEPT-6-ENOATE BENZATHINE SALT Ethyl (6E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)aminopyrimidin-5-y (3R,5S)-3,5-dihydroxyhept-6-enoate (1 g) was dissolved in ethanol (12 ml) at 25-30°C and added O.IN NaOH (16 ml) in 15 min at 25-30°C under reduced pressure. The reaction mixture was stirred for VA h at 25-30°C and ethanol was removed completely. Under reduce pressure DM water (25 ml) was added to the concentrated mass and washed with toluene (2 x 50 ml). Finally the aqueous layer was washed with 30% ethyl acetate and toluene mixture (2 x 50 ml). To the aqueous layer added a solution of benzathine diacetate (1 g) dissolved in DM water (10 ml) at 25-30°C and stirred for 3 hrs at 25-30°C. The resuhing product was filtered, washed with DM water (5 ml) and dried to constant weight to yield the title compound. Yield: 10.6 g. EXAMPLE 13 PREPARATION OF ROSUVASTATIN CALCIUM A/iA'-Dibenzylethylenediamine rosuvastatin salt (2 g) was dissolved in a mixture of ethyl acetate (30 ml) and DM water (30 ml) and cooled to 0-5°C. The above cold mixture was treated with aqueous hydrochloric acid (3 ml) at 0-5°C. The resulting clear solution was stirred for 10 min. The organic layer was separated, washed with water and cooled to 0-5°C. Aqueous sodium hydroxide (1 N, 30 ml) was added to the above organic layer and stirred at room temperature for 30 min for conversion of rosuvastatin acid to it sodium salt. Toluene (70 ml) was added to the above mixture and stirred for 10 min. The aqueous layer was separated and traces of solvent were removed at 40-45 °C under vacuum. The resulting clear aqueous layer was treated with an aqueous solution of calcium chloride (IN, 3 ml) and resulting rosuvastatin calcium was filtered and dried. Yield: 0.6 g Chromatographic purity: 99.3%. EXAMPLE 14 PREPARATION OF ROSUVASTATIN CALCIUM (3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]pyrimid yl]-3,5-dihydroxy-(6E)-heptenoic acid ethyl ester (5 g) was dissolved in a mixture of ethanol (25 ml) and tetrahydrofuran (2.5 ml) at 20-25°C under stirring. The reaction mass was cooled to 10-15°C and 1 N aqueous sodium hydroxide solution (9.82 ml) was added slowly at 10-15°C over a period of 20-25 min. Thereafter, the reaction mass was stirred for 2-3 h at 20-25°C and then concentrated under reduced pressure. A mixture of water (48 ml), ethanol (1.5 ml) and tetrahydrofiiran (1 ml) was added to the above reaction mass. The reaction mass was washed with a mixture of toluene (30 ml) and ethylacetate (20 ml). After washing, the aqueous layer was concentrated to a volume of approximately 35 ml at 35-40°C and cooled to 25-30°C. Aqueous calcium chloride (25 ml) (1.44 g of calcium chloride dihydrate was dissolved in 14 ml of water and the volume was make up to 25 ml) was added to the above aqueous layer at 25-30°C over a period of Vi hr and stirred the suspension for 3 h. The product obtained was filtered and dried under reduced pressure at 35-40°C till the moisture content is approximately 1.8 to 2%. Yield: 3.5 g WE CLAIM 1) An improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula I, wherein R3 represents C1-C4 straight chain or branched chain alkyl, aryl, substituted aryl, aralkyl; M represents Mg, Zn, Ca, Cu; n represents an integer selected from 1-3; Ri represents alkyl or alkoxy; m represents an integer selected from 0 or 1; in an organic solvent to obtain a compound of Formula VI, wherein R2 and R3 are as defined above c) deprotecting the compound of Formula VI with a suitable reagent in an organic solvent, water or mixtures thereof to obtain compound of Formula VII, wherein R3 is as defined above d) reducing the compound of Formula VII to obtain a compound of Formula VIII, wherein R3 as defined above e) hydrolyzing the compound of Formula VIII and converting into a salt of Formula I thereof. 2) The process according to claim 1, wherein protecting group employed is selected from tert.butyldimethylsilyl chloride, dihydropyran, trimethylsilyl chloride, methoxy methyl chloride, more preferably tert-butyl dimethylsilyl chloride. 3) The process according to claim 1, wherein the solvent employed in step (a) is selected from tetrahydrofuran, dioxane, dimethoxy ethane, dichloromethane, ethylene dichloride, dimethyl formamide, dimethylsulfoxide, N-methyl pyrrolidinone, sulfolane or mixtures thereof more preferably N,N-dimethylformamide. 4) The process according to claim 1, wherein the activating group employed in step (b) is 1,1 -carbonyldiimidazole, methyl chloroformate, ethyl chloroformate, phenyl chloroformate, 4-methoxyphenylchloroformate, 4-chlorophenylchloroformate, 2,4- dinitrophenylchloroformate, 4-trifluoromethylphenylchIoroformate, 4- nitrophenylchloroformate, 2-nitrophenylchloroformate, more preferably 1,1- carbonyldiimidazole. 5) The process according to claim 1, wherein the solvent employed in step (b) is selected from tetrahydrofuran, methyl tert.butylether, isopropyl ether, diisopropyl ether, N,N- dimethylformamide, methylene dichloride, acetonitrile, toluene, xylene, hexane, more preferably tetrahydrofuran. 6) The process according to claim 1, wherein the deprotection reaction is carried out using hydrofluoric acid, lithium fluoride, potassium fluoride, sodium fluoride, sulfonic acids such as para toluene sulfonic acids, methanesulfonic acids, trifluormethane sulfonic acid, organic acids such as formic acid, trifluro acetic acid, acetic acid, tetrabutyl ammonium fluoride, more preferably hydrofluoric acid. 7) The process according to claim 1, wherein the organic solvent used in step (c) is selected from tetrahydrofuran, acetonitrile, methanol, ethanol, methylene chloride, ethylene dichloride, toluene, xylene, or mixtures thereof more preferably acetonitrile. 8) The process according to claim 1, wherein the reduction in step (d) is carried out using metal borohydrides such as sodium borohydride, potassium borohydride, calcium borohydrate, more preferably sodium borohydride and a chelating agent such as trialkylborane or boronates selected from dialkyl alkoxy borane such as diethyl methoxy borane, dimethyl methoxy borane, diethyl ethoxy borane, dimethyl ethoxy borane, more preferably diethyl methoxy borane. 9) The process according to claim 1, wherein the reduction in step (d) is carried out in an inert solvent selected from tetrahydrofuran, lower alkanol or mixtures thereof. 10) The process according to claim 1, wherein the hydrolysis of step (e) is carried out using alkali metal hydroxides selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, more preferably sodium hydroxide.

Full Text

FIELD OF THE INVENTION
The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6" enoic acid calcium of Formula I,

The present invention is an improvement in or modification of the invention disclosed and claimed in our co-pending application no 277/CHE/2007,
BACKGROUND OF THE INVENTION
Rosuvastatin, which is an antihyperchlolesterolemic drug, is chemically known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium (2:1) salt of Formula I.

Rosuvastatin was for the first time disclosed in US 5,260,440. Rosuvastatin is being marketed under the proprietary name CRESTOR, as an oral tablet, for the treatment of hypercholesterolemia.
In view of the importance of rosuvastatin as a lipid-lowering agent, several synthetic methods have been reported in the literature to prepare rosuvastatin, some of which are summarized below:
US 5,260,440 disclose a process for preparing rosuvastatin in examples. The process is as shown below:

The difficulties in the above process are that the intermediate (A) is not obtained in pure form readily. Further, its purification is tedious and overall yield is extremely low. Even when intermediate (A) is obtained in pure form, further condensation with intermediate (11) to form rosuvastatin, does not result in rosuvastatin of right quality as the product contains unacceptable quantity of impurity levels.
WO 03/097614 A2 describes a modified procedure for the preparation of the starting material 4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-carboxaldehyde and its further conversion to rosuvastatin by condensing with methyl (3R)-3-[(tert-butyldimethylsilyl)oxy]-5-oxo-6-triphenylphosphoranylidene hexanoate. The condensed product was deprotected using methanesulfonic acid and subsequently converted to rosuvastatin calcium (2:1) salt.
WO 2004/052867 Al describes a process to prepare rosuvastatin by condensing 1-cyano (2S)-
2-[(tert-butyldimethylsilyl)oxy]-4-oxo-5-triphenylphosphoranylidenepentane with 4-(4-
fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino]pyrimidin-5-carbaldehyde and
subsequent deprotection of silyl group, followed by reduction and hydrolysis.
WO 2000/049014 Al discloses a novel chemical process for the manufacture of tert-butyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}-(4R,6S)-2,2-dimethyl[l,3]dioxan-4-yl)acetate, which comprises reaction of diphenyl {4-(4-fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino]pyrimidin-5-yl-methyl}phosphineoxide with tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-l,3-dioxan-4-yljacetate and its further conversion to rosuvastatin.
WO 2004/014872 Al describes a process for the manufacture of rosuvastatin calcium (2:1) salt, which comprises mixing a solution of calcium chloride with a solution of water soluble salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid. This process for the preparation of rosuvastatin employs the use of phosphorane side chain, the preparation of side chain requires eight

synthetic steps and involves expensive reagents. The process is both uneconomical and time consuming, hence not appropriate for commercial scale operation.
WO 2006/100689 Al discloses a process for preparation of rosuvastatin as shown below:

In the above scheme R1, R2, R3 represent substituted or unsubstituted phenyl and R4 represents an aliphatic residue selected from C1-C4 alkyl, R5 represents C1-C4 alkyl which is optionally

substituted by hydroxyl, R6 represents hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy, R7 represents aliphatic residue, R8 represents C1-C4 alkyl.
WO 2006/106526 Al describes the preparation of rosuvastatin as shown below:

In the above mentioned scheme R1, R2, R3 are substituted or unsubstituted phenyl and R4 is an aliphatic residue selected from C1-C4 alkyl, R5 represents C1-C4 alkyl, M is an alkali metal salt,

X represents a halogen, R6 represents C1-C4 alkyl which is optionally substituted by hydroxyl, R7 represents hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy, R8 is an aliphatic residue selected from C1-C4 alkyl.
As mentioned above though there are a number of processes available still there is a continuing need to identify alternative processes for the manufacture of rosuvastatin and its pharmaceutically acceptable salts. Such processes may, for example, when compared to previously known processes, be more convenient to use, be more suitable for large scale manufacture, give the product in a better yield, reduce the number of steps involved, use intermediates which are more easily isolated, require less complex purification techniques, use less expensive reagents and/or be more environmentally friendly.
We have now found an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-
2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept"6-enoic acid
calcium of Formula I
OBJECTIVE
The objective of the present invention is to provide an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium with high yield and high purity.
In yet another objective of the present invention is to provide an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium, which is simple, industrially applicable and economically viable.

SUMMARY OF THE INVENTION
The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5"yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula I,

wherein R3 represents CM straight chain or branched chain alkyl, aryl, substituted aryl, aralkyl; M represents Mg, Zn, Ca, Cu; n represents an integer selected from 1-3; Ri represents alkyl or alkoxy; m represents an integer selected from 0 or 1; in an organic solvent to obtain a compound of Formula VI,

wherein R3 is as defined above,
c) deprotecting the compound of Formula VI with a suitable reagent in an organic solvent,
water or mixtures thereof to obtain compound of Formula VII,

wherein R3 is as defined above,
d) reducing the compound of Formula VII to obtain a compound of Formula VIII,

DETAILED DESCRIPTION OF THE INVENTION
The compound of Formula III is protected with a suitable hydroxy protecting group selected from tert-butyldimethylsilyl chloride, 2,3-dihydropyran, trimethylsilylchloride, methoxymethyl chloride, more preferably tert-butyldimethylsilyl chloride. The hydroxy protection is carried out in an organic solvent in presence of bases like imidazole, triethylamine. The usage of base is essential for completion of silylation. The organic solvent used for the above silylation reaction is selected from tetrahydrofuran, dimethoxy ethane, dioxane, dichloromethane, ethylene dichloride, N, N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidinone, sulfolane, more preferably N,N-dimethylformamide etc. Also during this silylation reaction a suitable additive is added to accelerate silylation, which is selected from sodium iodide, potassium iodide, lithium iodide etc. The reaction is conducted at a temperature in the range of 0°-128°C, more preferably 50-80°C. The compound of Formula IV is isolated as an oily mass, which is sufficiently pure for the next step.
The hydroxy protected compound of Formula IV is treated with acid activator like 1,1-
carbonyldiimidazole, or methyl chloroformate, ethyl chloroformate, phenyl chloroformate, 4-
methoxyphenylchloroformate, 4-chlorophenylchloroformate, 2,4-dinitrophenylchloroformate,
4-trifluoromethylphenylchloroformate, 4-nitrophenylchloroformate, 2-
nitrophenylchloroformate, etc, more preferably 1,1-carbonyldiimidazole. This reaction is carried out in presence or absence of organic base. The organic base is selected from

triethylamine, pyridine etc. The resulting activated imidazolimide intermediate is subsequently treated with magnesium complex of monoalkyl malonate or zinc complex of monoalkyl malonate.
Magnesium complex of monoalkyl malonate can be prepared by treating 2 moles of malonic acid mono alky! ester with 1 mole of magnesium ethoxide. This homologation is conducted at a temperature between 0-100°C, preferably at ambient temperature. The organic solvent used in the homologation is selected from tetrahydrofuran, MiV-dimethylformamide, methylene dichloride, acetonitrile or mixtures thereof
Zinc complex of monoalkyl malonate can be prepared using different methods.
Process 1:
Zinc complex is prepared by reacting dialkyl zinc with 2 moles of lower alcohol, preferably
ethanol in an inert solvent such as tetrahydrofuran, toluene, hexane, methyl tert-butyl ether,
isopropyl ether or mixtures thereof, at -10°C to 40°C, preferably 5 to 25^C. 1 to 5 moles of
monoalkyl malonate, preferably 2 to 3 moles are added to this reaction mixture and stirred for
5 h 15 h, preferably 6 -12 h.
Process 2:
Zinc complex is prepared by reacting dialkyl zinc with 1 to 5 moles of monoalkyl malonate,
preferably 2 to 3 moles in an inert solvent such as tetrahydrofuran, toluene, hexane, methyl
tert-butyl ether, isopropyl ether or mixtures thereof., at ambient temperature for 5 h to 15 h,
preferably 6 h to 12 h.
Process 3:
Zinc complex is prepared by reacting zinc oxide with 1 to 5 moles of monoalkyl malonate in an
inert solvent such as tetrahydrofuran, toluene, hexane, methyl tert-butyl ether, isopropyl ether
or mixtures thereof, at ambient temperature for 5 h to 10 h. The water formed during the
course of reaction is co-distilled with an inert solvent such as toluene.
The metal complex of Formula V, is treated with acid activated compound of Formula IV, in an inert solvent such as tetrahydroftiran, acetonitrile, toluene, methyl tert-butyl ether, isopropyl

The deprotection of the compound of Formula VI to yield product of Formula VII, is carried out using acids having a general Formula HX wherein X represents halide or MX wherein X represents halogen, M is cation derived from like inorganic metal like Na"^, K^, Li^ etc or organic amine like N'4(R)4 where in R represents C1-C4 alkyl, straight or branched chain alkyl sulfonic acids such as para toluene sulfonic acids, methanesulfonic acids, trifluormethane sulfonic acid, organic acids such as formic acid, trifluroacetic acid, acetic acid in aqueous solvent or in a mixture of organic solvent at room temperature. The reaction is preferably conducted in organic solvent, water or mixtures thereof The organic solvent can be selected from tetrahydrofuran, acetonitrile, methanol, ethanol, dichloromethane, ethylene dichloride, toluene, xylene etc.
The compound of Formula VII is stereoselectively reduced with metal borohydride in presence of chelating agent like trialkylborane or boronates selected from dialkyl alkoxy boran such as diethyl methoxy borane, diethyl ethoxy borane, dimethyl ethoxy borane, dimethyl methoxy borane, more preferably diethyl methoxy borane. The stereoselective reduction is carried out in a mixture of inert solvent preferably tetrahydrofuran and lower alkanol, more preferably methanol at -78°C to -0°C. The metal borohydride employed is selected from sodium borohydride, potassium borohydride, calcium borohydride, more preferably sodium borohydride. After completion of reaction, excess borohydride is destroyed by acetic acid and

resulting compound of Formula VIII is extracted into an organic solvent. The organic layer is concentrated under reduced pressure to give crude compound of Formula VIII, which is purified or used as such for hydrolysis.
Saponification of compound of Formula VIII is carried out using a base, such as alkali metal hydroxide selected from sodium hydroxide, potassium hydroxide, calcium hydroxide. Preferably sodium hydroxide is used. The sodium salt of rosuvastatin thus obtained can be optionally isolated or the solution containing of rosuvastatin sodium is treated with benzathine acetate to get the corresponding benzathine salt, which can be further converted to rosuvastatin calcium. Alternatively, aqueous sodium salt of rosuvastatin can be treated with calcium ion source to give rosuvastatin calcium.
The preparation of compound of Formula III is elaborated in our co-pending application number 1994/CHE/2006 filed in Chennai, India.
The invention is illustrated with the following examples, which are provided by way of illustration only and should not be construed to limit the scope of the invention.
EXAMPLE 1
PREPARATION OF ETHYL.6-(E).7.[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2.[iV-
METHYL-iV-METHYLSULFONYLAMINO]PYRIMIDIN-5.YL]-(5S)-5-(t-
BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE
20% w/v Diethyl zinc in toluene (10 ml) was added to toluene (50 ml) and cooled to 10-15°C. Ethanol (1,9 ml) was added at the same temperature to the reaction mixture and stirred for 12 h at 25-30°C. Thereafter, the resulting clear solution was treated with a solution of monoethyl malonate (3.91 g) in toluene (50 ml) and stirred for 6 h at room temperature. Ethanol, a byproduct from the reaction mass was removed by co-distillation with toluene at 40-45°C. The resulting mass was diluted with toluene and further treated with a solution of Imidizolyl-(4E)-5[4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-A^-methylsulfonylamino]pyrimidin-5-yl]-(3S)-3-(t-butyldimethylsilyloxy)pentenoate (6 g) in toluene (30 ml) at room temperature and the

reaction mass was stirred for 40 h for completion of coupling reaction. After the reaction, mass was quenched with 5 % aqueous citric acid. The separated organic layer was washed with aqueous bicarbonate and finally with water. The crude product obtained after evaporation of solvent was purified by column chromatography. (Silica gel; Hexane : Ethylacetate mixture) Yield: 2 g
'HNMR (CDCb, 300 MHz): 003 (s, 6H), 0.85 (s, 9H), 1.24 (d, 6H), 1.26-1.29 (t, 3H), 2,49 (d,lH), 2.50 (d,lH), 2.65 (septet, IH), 3.4 (s,2H), 3.5 (s,3H), 3.5 (s, 3H), 3.56 (s, 3H), 4.1 (q, 2H), 4.56-4.58 (m, IH), 5.48 (dd, IH), 6.55 (d, IH), 7.1 (m, 2H), 7.58 (dd, 2H).
EXAMPLE 2
PREPARATION OF ETHYL-6-(E).7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[A^-
METHYL-7V-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL].(5S)-5-(t-
BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE
Zinc oxide (0.243 g) was suspended in toluene (50 ml) and monoethyl malonate (1.45 g) in toluene (10 ml) was added at 25-30°C and stirred for 3 h. To the resulfing clear solution imidazolyl-(4E)-5-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]-pyrimidin"5-yl]-(3S)-3-(t-butyldimethylsilyloxy) pentenoate (1.85 g) in tetrahydrofuran (5 ml) was added at 20-30°C and stirred the reaction mass at room temperature for 18 h. After the completion of coupling reaction, the reaction mass was quenched by the addition of aqueous citric acid and the organic layer was separated and washed with aqueous sodium bicarbonate followed by water. The organic layer was concentrated to yield crude compound. The crude compound obtained after evaporation of solvent was purified by column chromatography to yield the compound in pure form. Yield: 1.3 g

EXAMPLE 3
PREPARATION OF ETHYL-6-(E)-7-[4-(4.FLUOROPHENYL)-6-ISOPROPYL-2-[N-
METHYL-N.METHYLSULFONYLAMINO]PYRIMIDIN-5-YL].(5S)-5-(t-
BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE
20% w/w Diethyl Zinc in toluene (10 ml) was diluted with toluene under N2 atmosphere at 0-
5°C and then treated with a solution of monoethyl malonate (3.91 g) in toluene (10 ml) at 20-
30°C. The resulting solution was stirred for 4 h at 25-30°C for complex formation and further
treated with imidazolyl-(4E)-5[4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-A^-
ethylsulfonylamino]-pyrimidin-5yl]-3-(S)-3-(t-butyldimethylsilyloxy)-pentenoate (5.5 g) in toluene (15 ml) and stirred at room temperature for 21 h for completion of coupling reaction, and product precipitates out. The crude compound obtained was purified by column chromatography. Yield: 2.3 g
EXAMPLE 4
PREPARATION OF t.BUTYL-(6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[7V-
METHYL-iV-METHYLSULFONYLAMIN01PYRIDIN-5-YL}-(5S)-5-(t-
BUTYLDIMETHYLSILYLOXY)-3-OXOHEPTENOATE.
Diethyl zinc (10 ml, IM, solution in hexane) was added to tetrahydrofuran (20 ml) at 10-15^C and a mixture of ethanol (0.92 gm, 0.02 mol) and tetrahydrofuran (2ml) was added drop wise into the above diethyl zinc solution over a period of 10-15 min. The reaction mass was stirred at the same temperature for 30 min and mono-t-butyl malonate (3.2 gm, 0.02 mol) was added to the reaction mass drop wise after diluting with tetrahydrofuran (10 ml). The mixture was stirred for two hours and imidazolyl-5-{4-(4-fluorophenyl)-6-isopropyl-2-[A^-methy-A^-methylsulfonylamino]pyrimidin-5-yl}-(3S)-3-(t-butyldimethylsilyloxy] heptenoate (2.5gm), dissolved in tetrahydrofuran (10 ml) was added to it slowly over a period of 20 min. The reaction was stirred for 16 h at 20-25°C and quenched by adding water (20 ml) drop wise into the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with water (50 ml) and dried

over sodium sulfate. The solvent was distilled out under reduced pressure (50-100 mm Hg) at
35-40°C to obtain the crude product as an oily mass, which was further purified by column
chromatography using hexane, ethyl acetate. (9:1 v/v) as an eluant.
Yield: 2.5 g
^HNMR (CDCl3,300 MHz): 0.1 (s, 6H), 0.93 (s,QH), 1.27 (d, 6H), 1.48 (s, 9H), 2.53 (dd, 2H),
3.33 (septet, IH), 2.36 (s, 2H), 3.53 (s, 3H), 3.58 (s, 3H), 4.53^7.55 (m, IH), 5.52 (dd, IH),
6.58 (d, IH), 7.01 (t, 2H), 7.62 (dd, 2H).
EXAMPLE 5
PREPARATION OF t.BUTYL-(6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[N-METHYL-N-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL}.(5S)-5-HYDROXY-3-OXO HEPTENOATE
t-Butyl(6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino] pyrimidin-5-yl}-(5S)-5-[t-butyl dimethylsilyloxy)-3-oxo heptenoate (2.5 gm) was dissolved in tetrahydrofuran (10 ml) at 25-30°C and tetrabutyl ammonium fluoride (5 ml, IM solution in tetrahydrofuran) was added to it drop wise over a period of 15 min. The mixture was stirred for 30 min at 25-30°C and quenched with aqueous sodium carbonate (25 ml, 10 % w/v). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with D.M water (25 ml) and solvent was evaporated under reduced pressure at 35-40°C to obtain the product as an oily mass. The product obtained was used as such for the subsequent reaction without further purification. Yield: 2 g
1H NMR (CDCU, 300MHz): L27 (d, 6H), 1.47 (S, 9H), 2.39 (d, 2H), 3.37 (septet, IH), 3.38 (brs, IH), 3.53 (s, 3H), 3.58 (s, 3H), 4.51-4.53 (m, IH), 5.5 (dd, IH), 6.65 (d, IH), 7.09 (f, 2H), 7.65 (dd, 2H).

EXAMPLE 6
PREPARATION OF t-BUTYL-(6E)-7-{4-(4.FLUOROPHENYL)-6-ISOPROPYL-2-[A^-METHYL-7V-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL}-(3R,5S)-3,5-DIHYDROXY HEPTENOATE
t-Butyl-(6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[A^-methyl-iV-methylsulfonyl-amino]pyrimidin-5-yI}-(5S)-5-hydroxy-3-oxo heptenoate (2 g, 0.003 mol) was dissolved in tetrahydrofuran (54 ml) and methanol (14 ml) at 25-30°C under nitrogen atmosphere. The mixture was cooled to -78°C and diethylmethoxy borane (1 ml, 48 % solution in tetrahydrofuran, 0.004 mol) was added to it drop wise at -78°C over a period of 10 min. The mixture was stirred at -75°C to -78°C for one hour and sodium borohydride (0.14 gm, 0.003 mol) was added to it slowly over a period of 15 min. It was stirred for 2 h at -75°C to -78°C and quenched by adding acetic acid (2 ml) at -78°C. Saturated aqueous sodium bicarbonate solution (50 ml) was added to it and stirred for 15 min. The organic layer was separated and aqueous layer was extracted with ethyl acetate (25 ml). The combined organic layer was washed with water (25 ml) and dried over sodium sulfate. The solvent was distilled out at 35-40°C under reduced pressure to obtain the title compound. Yield: 2 g
^HNMR: 1.27 (d, 6H), 1.47 (s, 9H), 1.50-1.58 (m, IH), 2.38 (d, 2H), 3.37 (septet, IH), 3.51 (s, 3H), 3.57 (s, 3H), 3.63 (bs, IH), 3.80 (bs, IH), 4.15-4.18 (m, IH), 4.44-4.48 (m, IH), 5.46 (dd, IH), 6.64 (d, IH), 7.09 (t, 2H), 7.65 (dd, 2H).
EXAMPLE 7
PREPARATION OF ETHYL-6-(E).7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[7V-METHYL-N-METHYLSULFONYLAMINO]PYRIMIDIN-5-YL]-(5S)-HYDROXY-3-OXO HEPTENOATE
Ethyl 6-(E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]-pyrimidin-5-yl]-(5S)-5-(t-butyldimethylsilyloxy)-3-oxo heptenoate (5 g) in acetonitrite (3 ml) was added to aqueous hydrofluoric acid (6.2 ml, 48 % w/w) at 0-5°C in 15 min. The temperature of the reaction mass was raised to 25-30°C and stirred for 2 h for completion of silyl cleavage. The

reaction mixture was basified with aqueous sodium bicarbonate solution and the product was extracted with ethyl acetate (50 ml). The ethyl acetate layer was washed with water, dried over sodium sulphate and concentrated to give crude product (3 g). The crude product obtained was purified using column chromatography with ethyl acetate / hexane as eluant to yield pure title compound as an oil.
WMR (CDCI3, 300 MHz): 1.25 (d, 6H), 1.27-1.29 (t, 3H), 2,65 (d, 2H), 3.34 (septet, IH), 3.44 (s, 2H), 3.52 (s, 3H), 3.57 (s, 3H), 4.22 (t, 2H), 4.51-4.55 (m, IH), 5.4 (dd, IH), 6.64 (d, IH), 7.08 (m, 2H), 7.63 (dd, 2H).
EXAMPLE 8
PREPARATION OF (4E)-5-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL-
(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL}-(3S)-3-(0-TERT-
BUTYLDIMETHYLSILYL)-4-PENTENOICACID
tert-Butyldimethylsilyl chloride (7.6 g, 0.05 mol) was dissolved in A^,7V-dimethylformamide (25 ml) and anhydrous potassium iodide (8.4 g, 0.05 ml) was added to it at 25°C. The mixture was heated to 60°C and stirred for 30 min. Triethylamine (7 g, 0.06 mol) was added to the above hot reaction mixture and stirred for 10 min at 60°C. Subsequently (4E)-5-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyridin-5-yl-(3S)-3-hydroxy-4-pentenoic acid (10 g, 0.02 mol) was dissolved in iV^A^-dimethylformamide (25 ml) and added to the above reaction mixture drop wise over a period of 30 min at 60°C. The reaction mass was further stirred at 60°C for 2 h and cooled to room temperature. The reaction mass was quenched by adding DM water (50 ml) and product was extracted in toluene (2 x 50 ml). The toluene layer was washed with aqueous sodium bicarbonate (50 ml) followed by aqueous saturated sodium chloride (50 ml). The solvent was removed under reduced pressure to yield title compound as an oily mass, which was pure enough for the subsequent reaction. Yield: 12 g (95%)
^HNMR (CDCI3, 300 MHz): 0.05 (s, 6H), 0.89 (s, 9H), 1.27-1.30 (m, 6H), 2.38-2.50 (m, 2H), 3.40 (m, IH), 3.54 (s, 3H), 3.59 (s, 3H) 4.52 (brs, IH), 5.50-5.61 (m, IH), 6.58 (d, IH, J=15Hz), 7.0-7.18 (m, 2H), 7.60-7.66 (m, 2H).

EXAMPLE 9
PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6.ISOPROPYL.2-
[METHYL-(METHYLSULFONYL)AMINO]PYRIMIDIN-5.YL}.(5S)-5-(0-
TERTBUTYLDIMETHYLSILYL)-3-OXO-HEPT-6-ENOATE
(4E)-5-{4-(4-Fluorophenyl)-6"isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-(3S)-3-(0-tert-butyldimethylsilyl)-4-pentenoic acid (10 g, 0.018 mol) was dissolved in tetrahydrofliran (180 ml) and a solution of 1,1-carbonyldiimidazole (5.3 g, 0.03 mol) in tetrahydrofuran (30 ml) was added to the above reaction mass drop wise over a period of 30 min. The reaction mass was stirred overnight and magnesium salt of ethyl malonate (prepared in situ by stirring magnesium alkoxide (2.27 g) and monomethyl malonate (5.0 g) in tetrahydrofuran 30 ml at 25°C) was added drop wise into the reaction mass. The reaction mass was stirred for additional 20 h. After completion of the reaction, tetrahydrofuran was distilled out and redissolved the mass in a mixture of toluene (500 ml) and ethyl acetate (100 ml). The resulting organic layer was washed with aqueous sodium carbonate (500 ml) followed by DM water (2 x 500 ml). Thereafter, the organic layer was concentrated completely at 45-50°C under reduced pressure to obtain the crude title compound. The crude compound obtained was used for the subsequent reaction without ftirther purification. Yield: 8.75 g
EXAMPLE 10
PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5^YL}-(5S)-5-HYDROXY-3-OXO HEPT-6-ENOATE
Ethyl (6E)-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-(5S)-5-(0-tertbutyldimethylsilyl)-3-oxo-hept-6-enoate (10 g, 0.016 mol) was dissolved in acetonitrile (250 ml) at 25°C and the reaction mixture was cooled to 0°C. Hydrofluoric acid (48 %, 15 ml) was diluted in acetonitrile (250 ml) and added slowly to the above reaction mass over a period of 20 min at 0-5°C. After addition, the reaction mass was quenched by addition of 10 % aqueous sodium bicarbonate solution (50 ml). The organic layer was separated and the

aqueous layer was extracted with ethyl acetate (50 ml). The combined organic layer was
washed with DM water (50 ml) and solvent distilled out under vacuum at 40-45°C to obtain the
product as an oily mass.
Yield: 8.25 g (66%)
'HNMR (CDCI3, 300 MHz): 1.25-1.32 (m, 9H), 2.67 (d, 2H, J=6Hz), 3.30-3.39 (m, IH), 3.46
(s, 2H), 3.53 (s, 3H), 3.59 (s, 3H), 4.12-4.20 (m, 2H), 4.56 (brs, IH), 5.40 (dd, J=15Hz, 6Hz),
6.68 (d, J=15Hz, IH), 7.09-7.28 (m, 2H), 7.62-7.67 (m, 2H).
EXAMPLE 11
PREPARATION OF ETHYL (6E)-7-{4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-
[METHYL-(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL}(3R,5S)-3,5-
DIHYDROXY-HEPT-6-ENOATE
Ethyl (6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl}(5S)-3-oxo-hept-6-enoate (10 g, 0.02 mol) was dissolved in a mixture of tetrahydrofuran (500 ml) and methanol (70 ml) at 25°C. The mixture was cooled to -78°C and diethylmethoxyborane (48 % in tetrahydrofuran, 5 ml, 0.02 mol) was added to the above cooled reaction mass at -75°C to -78°C over a period of 20 min. The reaction mass was stirred at -75°C to -78°C for 30 min before adding sodium borohydride (1 g, 0.02 m). The mixture was stirred for another 2 h at -78°C and quenched by adding acetic acid (13 g). Thereafter, saturated sodium bicarbonate solution (500 ml) was added to it and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with ethyl acetate (250 ml) and the combined organic layer was washed with DM water (250 ml). The organic layer obtained during the above process was concentrated at 40-45 °C under vacuum to get the crude product, which was used for hydrolysis as such without further purification. Yield: 10 g (99%)
'HNMR (CDCI3, 300 MHz): 1.22-1.30 (m, 9H), 1.46-1.53 (m, 2H), 2.46 (d, J=6Hz, 2H), 3.34-3.38 (m, IH), 3.52 (s, 3H), 3.58 (s, 3H), 4.15-4.28 (m, 2H), 4.95 (brs, IH), 5.45 (dd, J=15Hz, 6Hz).

EXAMPLE 12
PREPARATION OF ETHYL (6E)-7-(4-(4.FLUOROPHENYL).6-ISOPROPYL-2-
[METHYL(METHYLSULFONYL)AMINOPYRIMIDIN-5-YL] (3R,5S)-3,5-
DIHYDROXYHEPT-6-ENOATE BENZATHINE SALT
Ethyl (6E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)aminopyrimidin-5-y (3R,5S)-3,5-dihydroxyhept-6-enoate (1 g) was dissolved in ethanol (12 ml) at 25-30°C and added O.IN NaOH (16 ml) in 15 min at 25-30°C under reduced pressure. The reaction mixture was stirred for VA h at 25-30°C and ethanol was removed completely. Under reduce pressure DM water (25 ml) was added to the concentrated mass and washed with toluene (2 x 50 ml). Finally the aqueous layer was washed with 30% ethyl acetate and toluene mixture (2 x 50 ml). To the aqueous layer added a solution of benzathine diacetate (1 g) dissolved in DM water (10 ml) at 25-30°C and stirred for 3 hrs at 25-30°C. The resuhing product was filtered, washed with DM water (5 ml) and dried to constant weight to yield the title compound. Yield: 10.6 g.
EXAMPLE 13
PREPARATION OF ROSUVASTATIN CALCIUM
A/iA'-Dibenzylethylenediamine rosuvastatin salt (2 g) was dissolved in a mixture of ethyl acetate (30 ml) and DM water (30 ml) and cooled to 0-5°C. The above cold mixture was treated with aqueous hydrochloric acid (3 ml) at 0-5°C. The resulting clear solution was stirred for 10 min. The organic layer was separated, washed with water and cooled to 0-5°C. Aqueous sodium hydroxide (1 N, 30 ml) was added to the above organic layer and stirred at room temperature for 30 min for conversion of rosuvastatin acid to it sodium salt. Toluene (70 ml) was added to the above mixture and stirred for 10 min. The aqueous layer was separated and traces of solvent were removed at 40-45 °C under vacuum. The resulting clear aqueous layer was treated with an aqueous solution of calcium chloride (IN, 3 ml) and resulting rosuvastatin calcium was filtered and dried. Yield: 0.6 g
Chromatographic purity: 99.3%.

EXAMPLE 14
PREPARATION OF ROSUVASTATIN CALCIUM
(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-methylsulfonylamino]pyrimid yl]-3,5-dihydroxy-(6E)-heptenoic acid ethyl ester (5 g) was dissolved in a mixture of ethanol (25 ml) and tetrahydrofuran (2.5 ml) at 20-25°C under stirring. The reaction mass was cooled to 10-15°C and 1 N aqueous sodium hydroxide solution (9.82 ml) was added slowly at 10-15°C over a period of 20-25 min. Thereafter, the reaction mass was stirred for 2-3 h at 20-25°C and then concentrated under reduced pressure. A mixture of water (48 ml), ethanol (1.5 ml) and tetrahydrofiiran (1 ml) was added to the above reaction mass. The reaction mass was washed with a mixture of toluene (30 ml) and ethylacetate (20 ml). After washing, the aqueous layer was concentrated to a volume of approximately 35 ml at 35-40°C and cooled to 25-30°C. Aqueous calcium chloride (25 ml) (1.44 g of calcium chloride dihydrate was dissolved in 14 ml of water and the volume was make up to 25 ml) was added to the above aqueous layer at 25-30°C over a period of Vi hr and stirred the suspension for 3 h. The product obtained was filtered and dried under reduced pressure at 35-40°C till the moisture content is approximately 1.8 to 2%. Yield: 3.5 g

WE CLAIM
1) An improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula I,

wherein R3 represents C1-C4 straight chain or branched chain alkyl, aryl, substituted aryl, aralkyl; M represents Mg, Zn, Ca, Cu; n represents an integer selected from 1-3; Ri represents alkyl or alkoxy; m represents an integer selected from 0 or 1; in an organic solvent to obtain a compound of Formula VI,

wherein R2 and R3 are as defined above
c) deprotecting the compound of Formula VI with a suitable reagent in an organic solvent,
water or mixtures thereof to obtain compound of Formula VII,

wherein R3 is as defined above
d) reducing the compound of Formula VII to obtain a compound of Formula VIII,

wherein R3 as defined above
e) hydrolyzing the compound of Formula VIII and converting into a salt of Formula I thereof.
2) The process according to claim 1, wherein protecting group employed is selected from
tert.butyldimethylsilyl chloride, dihydropyran, trimethylsilyl chloride, methoxy methyl
chloride, more preferably tert-butyl dimethylsilyl chloride.
3) The process according to claim 1, wherein the solvent employed in step (a) is selected from
tetrahydrofuran, dioxane, dimethoxy ethane, dichloromethane, ethylene dichloride,
dimethyl formamide, dimethylsulfoxide, N-methyl pyrrolidinone, sulfolane or mixtures
thereof more preferably N,N-dimethylformamide.
4) The process according to claim 1, wherein the activating group employed in step (b) is
1,1 -carbonyldiimidazole, methyl chloroformate, ethyl chloroformate, phenyl
chloroformate, 4-methoxyphenylchloroformate, 4-chlorophenylchloroformate, 2,4-
dinitrophenylchloroformate, 4-trifluoromethylphenylchIoroformate, 4-
nitrophenylchloroformate, 2-nitrophenylchloroformate, more preferably 1,1-
carbonyldiimidazole.
5) The process according to claim 1, wherein the solvent employed in step (b) is selected from
tetrahydrofuran, methyl tert.butylether, isopropyl ether, diisopropyl ether, N,N-
dimethylformamide, methylene dichloride, acetonitrile, toluene, xylene, hexane, more
preferably tetrahydrofuran.

6) The process according to claim 1, wherein the deprotection reaction is carried out using hydrofluoric acid, lithium fluoride, potassium fluoride, sodium fluoride, sulfonic acids such as para toluene sulfonic acids, methanesulfonic acids, trifluormethane sulfonic acid, organic acids such as formic acid, trifluro acetic acid, acetic acid, tetrabutyl ammonium fluoride, more preferably hydrofluoric acid.
7) The process according to claim 1, wherein the organic solvent used in step (c) is selected from tetrahydrofuran, acetonitrile, methanol, ethanol, methylene chloride, ethylene dichloride, toluene, xylene, or mixtures thereof more preferably acetonitrile.
8) The process according to claim 1, wherein the reduction in step (d) is carried out using metal borohydrides such as sodium borohydride, potassium borohydride, calcium borohydrate, more preferably sodium borohydride and a chelating agent such as trialkylborane or boronates selected from dialkyl alkoxy borane such as diethyl methoxy borane, dimethyl methoxy borane, diethyl ethoxy borane, dimethyl ethoxy borane, more preferably diethyl methoxy borane.
9) The process according to claim 1, wherein the reduction in step (d) is carried out in an inert solvent selected from tetrahydrofuran, lower alkanol or mixtures thereof.
10) The process according to claim 1, wherein the hydrolysis of step (e) is carried out using alkali metal hydroxides selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, more preferably sodium hydroxide.

Documents:

http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=p5iYdIrLj/a9lrJNvvFIOg==&loc=egcICQiyoj82NGgGrC5ChA==

« Previous Patent

Next Patent »

Patent Number

279304

Indian Patent Application Number

1121/CHE/2007

PG Journal Number

03/2017

Publication Date

20-Jan-2017

Grant Date

17-Jan-2017

Date of Filing

29-May-2007

Name of Patentee

AUROBINDO PHARMA LIMITED

Applicant Address

AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA

Inventors:

#	Inventor's Name	Inventor's Address
1	NANGI GANGADHAR BHIMA SHANKAR	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA
2	MALLELA SAMBHU PRASAD SARMA	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA
3	SUKUMAR NANDI	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA
4	RAMESH DANDALA	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA
5	BURIDIPAD SUNIL KUMAR	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA
6	MEENAKSHI SUNDERAM SIVAKUMARAN	AUROBINDO PHARMA LTD, PLOT NO 2, MAITRIVIHAR, AMEERPET, HYDERABAD-500 038, ANDHRA PRADESH, INDIA

PCT International Classification Number

C07D239/42

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1			NA